Chiesi Expands Its Rare Disease Reach With $1.48bn Amryt Buyout

US Expansion Also Part Of Strategy

The privately owned company currently earns most of its revenues in respiratory medicine in Europe, but has set its sights on expanding in rare diseases and the US market.

Chiesi
• Source: Chiesi

Chiesi has made its biggest ever acquisition with the $1.48bn buyout of rare disease specialist company Amryt Pharma to further its US and rare disease ambitions.

The privately owned, Italy-headquartered company currently earns the lion’s share of its revenues from its portfolio of respiratory medicines in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip